STAT+: Cadre of radiopharmaceuticals experts pushes the bounds in cancer therapy

Radiopharmaceuticals are emerging as a powerful oncology tool, using targeted radiation to destroy cancer cells and extend survival. Louise Emmett, a leading figure who collaborates with AstraZeneca and Novartis, is urging developers to be bolder and dose patients more frequently than current practice allows. She and like-minded experts believe the industry is overly cautious about these therapies' potential.

However, as the field has expanded over the past five years, safety issues have surfaced: experimental therapies have inadvertently affected patients' kidneys, liver, or bone marrow. These adverse effects have already forced at least one company to shut down and created setbacks at other organizations. The tension between pushing higher dosing frequencies and managing toxicity is a central challenge for the field.